Penetration of efavirenz into the male genital tract: Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men
Taylor S., Reynolds H., Sabin CA., Drake SM., White DJ., Back DJ., Pillay D.
Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.